AstraZeneca (AZN) News
NYSE: AZNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
159.20+0.42 (+0.26%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AZN news summary
We found 36 recent headlines mentioning AstraZeneca (AZN): 15 in the past week and 29 in the past 30 days, most often from Nasdaq, Seeking Alpha. For price context, AZN is up 0.26% at $159.20. The most recent story, "Alnylam vs. Ionis: Here's the Better Bad-News Buy", was published by Nasdaq on Oct 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest AstraZeneca headlines
- Alnylam vs. Ionis: Here's the Better Bad-News BuyKey PointsAlnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra.NasdaqPFE, IONS, ALNY, AZN
- Cancer Stocks to Consider as Oncology Innovation AcceleratesOncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.NasdaqABT, PFE, MMSI, AZN
- 2 Growth Stocks to Buy in OctoberKey PointsGrail’s stock could skyrocket if the FDA approves Galleri.NasdaqMRK, LLY, PFE, VEEV
- Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 ResultsPFE's oncology growth in Q3 hinges on key drug sales, biosimilars and progress across a late-stage pipeline.NasdaqPFE, AZN, JNJ, MRK
- Myriad Genetics, SOPHiA GENETICS Partner With AstraZeneca On Prostate Cancer PrGIS(RTTNews) - Myriad Genetics (MYGN) and SOPHiA GENETICS (SOPH) announced a collaboration with AstraZeneca (AZN) to advance a new prostate cancer-specific genomic instability score, or PrGIS, for…NasdaqAZN, MYGN, SOPH
- Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technologySeeking Alpha
- How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.NasdaqLLY, AZN, PFE, MRK
- Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.NasdaqIRWD, AZN, ABBV
- Astrazeneca (AZN) Exceeds Market Returns: Some Facts to ConsiderIn the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.Nasdaq
- Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?Merck's 7% dip may offer a buying opportunity as Keytruda drives growth and new products and pipeline assets strengthen its post-2028 outlook.NasdaqMRK, AZN, MRNA
- AstraZeneca Opens New $1 Bln R&D Hub To Strengthen Global Drug Research(RTTNews) - Global biopharmaceutical company, AstraZeneca PLC (AZN) announced that it has opened a new strategic research and development (R&D) centre in Kendall Square, Cambridge, Massachusetts.Nasdaq
- AstraZeneca CEO Soriot says drugmaker can grow without big acquisitionSeeking Alpha
- SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosSummit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.NasdaqSMMT, AZN, PFE
- FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line SettingLLY's Jaypirca gains FDA approval for first-line CLL/SLL, with strong trial results and rising sales bolstering its cancer portfolio.NasdaqLLY, AZN, JNJ, ABBV
- Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca(RTTNews) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of ivonescimab,…NasdaqAZN, SMMT
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data(RTTNews) - The week brought a fresh round of developments across the biotech and pharma landscape, with companies advancing new therapies through regulatory milestones, clinical studies, strategic…NasdaqABBV, AZN, CBLL, CDXS
- Sanofi, Regeneron Expand Immunology Alliance With New AntibodiesSNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.NasdaqREGN, SNY, AZN
- J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to WatchJNJ's Innovative Medicine segment is poised for another quarter of growth, with oncology and new launches helping offset Stelara's biosimilar-driven decline.NasdaqJNJ, AZN, AMGN, ABBV
- Daiichi Sankyo, AstraZeneca, Summit Partner On Datroway- Ivonescimab Cancer Studies(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZeneca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in…NasdaqAZN, SMMT
- Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab(RTTNews) - Daiichi Sankyo (4568.TS) and AstraZenca (AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics (SMMT) to evaluate Datroway (datopotamab deruxtecan) in…NasdaqAZN, SMMT
- Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to NoteAstrazeneca (AZN) closed at $164.21 in the latest trading session, marking a -1.17% move from the prior day.Nasdaq
- Summit Shares Jump on $2B Strategic Investment From AstraZenecaSMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.NasdaqSMMT, AZN, PFE
- AstraZeneca Invests $2 Billion In Summit, Expands Cancer Drug Collaboration; Stock Up(RTTNews) - AstraZeneca (AZN) has agreed to make a $2 billion strategic equity investment in Summit Therapeutics (SMMT) while launching a clinical collaboration aimed at advancing new cancer…NasdaqAZN, SMMT
- Sanofi's New Drugs Poised to Drive Growth Beyond DupixentSNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.NasdaqSNY, REGN, AZN, LLY
- Why AstraZeneca Still Looks Underrated Despite Strong EPS MomentumSeeking Alpha
- Ionis Delivers Positive Late-Stage Results for Two Partnered DrugsIONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.NasdaqIONS, AZN, NVS
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead(RTTNews) - Biotech investors tracked a busy week marked by regulatory approvals, strategic collaborations, workforce restructuring and key clinical trial readouts.NasdaqAEMD, AZN, BBNX, BIIB
- Bavarian Nordic Appoints Stenvall As President & CEO(RTTNews) - Danish biopharmaceutical company Bavarian Nordic A/S (BAVA.CO) on Thursday announced the appointment of Tarja Stenvall as President and Chief Executive Officer, effective October 15, 2026.NasdaqAZN, PFE, SNY
- AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open LongSeeking Alpha
- AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress TranscriptSeeking Alpha
- AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) Congress - SlideshowSeeking Alpha
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB
- Top Stock Reports for AMD, Costco & AstraZenecaAMD, Costco and AstraZeneca headline today's stock reports, with AI demand, membership growth and drug pipelines shaping their outlooks.NasdaqAZN, AMD, COST, PEBK
- Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks(RTTNews) - This week's global biopharma roundup captured a mix of regulatory approvals, strategic partnerships, acquisitions, and merger activity, alongside clinical trial breakthroughs and halts.…NasdaqALIT, ARGX, AZN, BMRN
- AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?Seeking Alpha
- AstraZeneca, Bristol Myers Squibb To Merge? Let's Consider The Pros And ConsSeeking AlphaBMY, AZN